Bruker launches new nanoElute® –


At the International Mass Spectrometry Conference (IMSC 2022), Bruker+Corporation (Nasdaq: BRKR) today announced the launch of the new nanoElute® 2 nano-LC, MetaboScape® and TASQ® 2023 software supporting fluxomics, and the latest advancements in PaSER™ Intelligent Acquisition to enhance protein-protein interaction (PPI) research and metaproteomics applications.

This press release is multimedia. View the full press release here:

The nanoElute® 2, a high-performance nanoflow liquid chromatography system with an intuitive and flexible user interface, covering a wide range of applications from single cell to high-throughput routine proteomics (Photo: Business Wire)

The next generation nanoElute® 2 combines exceptional nano-LC chromatography performance with heavy-duty high-pressure switching valves and hand-tightened torque-limiting capillaries for zero-dead-volume, leak-free connections without the risk of over-tightening or damaging capillaries. The nanoElute 2 features a further improved nano-LC pump design and an intuitive and flexible user interface covering a wide range of applications from single cell proteomics to plasma proteomics. The nanoElute 2 now also supports label-free ProteoCHIP® for the CellenONE platform for high-sensitivity single-cell proteomics.

Dr Henrik JohanssonSenior Researcher in Cancer Proteomics at the Department of Oncology-Pathology at Karolinska Institutet in Sweden, said: “The ‘dissolution’ workflow on the nanoElute 2 now perfectly supports our proteomics sample preparation performed by the robotic platform in 96 or 384 well plates. The nanoElute 2 dissolves tryptic peptides directly into the plate prior to injection, avoiding manual intervention and streamlining our workflows.

The last MetaboScape 2023 provides streamlined collision cross-section (CCS) compatible metabolic profiling and annotation workflows covering timsTOF 4D data acquisition through to the most reliable annotations for lipids and metabolites. New features include improved 4D peak detection and integration, accelerated processing, and intelligent fusion of positive and negative ion data. Powerful automated prediction of CCS values ​​from chemical structures in spectral libraries leverages accurate CCS values ​​measured on the timsTOF.

Additionally, to support the metabolomics community’s focus on quality, MetaboScape 2023 now offers better means of assessing data quality in large-scale studies, while TASQ 2023 extends target screening and quantification by CCS-enabled MOMA events. Finally, improvements in stable isotope labeling methods simplify large-scale labeling experiments.

Professor Nils FaergemanDepartment of Biochemistry and Molecular Biology at the University of Southern Denmark, said: “The new TASK fluxomics has streamlined our stable isotope labeling experiments on our timsTOF instrument. Built-in natural abundance correction and fractional enrichment calculations, along with manual review capabilities, allow us to generate results with high confidence for our small molecule isotope tracing studies.

At IMSC, Buker is also presenting the new MALDI HiPLEX-IHC workflow for multiplex imaging of protein targets. MALDI HiPLEX-IHC combines Bruker’s IntelliSlides® automated MALDI workflow with AmberGen Miralys Antibody-based photocleavable mass tags for spatial localization of target proteins across tissue sections. Key workflow advantages include the slide’s full field of view and the ability to multiplex dozens to over a hundred protein targets from FFPE sections or fresh frozen tissue, as well as the multiomics capability to overlay mass specification images of metabolites, lipids and glycans with protein targets of the same rubric.

Dr. Ron HeerenEmeritus Professor and Limburg Co-Chair of the Multimodal Molecular Imaging Institute (M4I) in Maastricht, added: “At M4I, we are developing workflows and techniques to contextualize the role of individual cells in disease and determine how interactions between cells affect cellular states locally. and over long distances. MALDI HiPLEX-IHC provides a seamless platform to integrate protein expression information into the key projects we collaborate on with our experimental pathology team.

At IMSC, Bruker is also advancing its real-time research capabilities in proteomics bioinformatics using PaSER™. Intelligent instrument control using all 4e The dimension of accurate large-scale CCS data promises far greater insights, from post-translational modifications of the epiproteome to substoichiometric analytes in targeted approaches.

Dr. Mathieu Lavallee-Adam, associate professor at the University of Ottawa and the Ottawa Institute for Systems Biology in Ottawa, Canada, said: “We use machine learning, such as Bayesian inference, artificial neural networks and logistic regression classifiers, with large-scale proteomics data to derive biological insights into cellular mechanisms and disease processes. Biological samples are often sample-limited, requiring the extraction of so much information in single analyses, now complemented by on-the-fly adjustments to mass spectrometry parameters. Bruker’s intelligent feedback control via PaSER allows us to rapidly prototype feedback-based bioinformatics modules for use by the community. We are excited to collaborate with Bruker to further intelligent feedback-based acquisition for the study of protein-protein interactions and metaproteomics.

About Bruker Corporation (Nasdaq: BRKR)

Bruker enables scientists to make groundbreaking discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at the molecular, cellular and microscopic levels. Working closely with our customers, Bruker enables innovation, improved productivity and customer success in life science molecular and cellular biology research, applied and pharmaceutical applications, microscopy and nanoanalysis, as well as in industrial applications. Bruker offers high-value, differentiated diagnostic and life science systems and solutions in the areas of preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology , structural functional biology and condensates, as well as clinical microbiology and molecular diagnostics. Please visit


See the source version on


Comments are closed.